Is myelomeningocele a distinct subgroup within neuromuscular early-onset scoliosis (M-EOS)? A clinical and radiographic comparison after graduation from growing rod treatment.
Ataberk Beydemir, Rafik Ramazanov, Mehmet Berktas, Mehmet Ayvaz, Halil Gokhan Demirkiran, Muharrem Yazici
{"title":"Is myelomeningocele a distinct subgroup within neuromuscular early-onset scoliosis (M-EOS)? A clinical and radiographic comparison after graduation from growing rod treatment.","authors":"Ataberk Beydemir, Rafik Ramazanov, Mehmet Berktas, Mehmet Ayvaz, Halil Gokhan Demirkiran, Muharrem Yazici","doi":"10.1007/s43390-026-01558-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim was to compare clinical and radiographic outcomes between myelomeningocele (MMC) and other neuromuscular early-onset scoliosis (EOS) patients following graduation from growing rod treatment and to evaluate whether MMC should be considered a distinct subgroup within the classification of EOS.</p><p><strong>Methods: </strong>This single-center retrospective cohort study included 26 patients with neuromuscular EOS (10 with MMC, 16 with other neuromuscular etiologies) treated with traditional or magnetically controlled growing rods between 2004 and 2023, all of whom achieved graduation and had a minimum of 2-year of post-graduation follow-up. Demographic, clinical, radiographic, and complication data were analyzed. Complication burden was assessed using unplanned return to the operating room (UPROR), modified Clavien-Dindo-Sink grading, and negative binomial regression.</p><p><strong>Results: </strong>Wound-related complications were significantly more frequent in the MMC group (80.0% vs. 6.2%, p = 0.002). The MMC patients had a higher complication burden (mean 3.3 ± 2.3 vs. 0.9 ± 1.4, p = 0.003), more multiple reoperations (≥ 2 UPROR: 70.0% vs. 0.0%, p = 0.007), more severe complications (modified Clavien-Dindo-Sink grade 3b: 70.0% vs. 25.0%, p = 0.016), and a 3.52-fold higher overall complication rate (IRR = 3.52, 95% CI 1.63-10.80). Spinal growth and sagittal alignment were also significantly compromised in the MMC patients.</p><p><strong>Conclusion: </strong>MMC patients demonstrate a markedly distinct complication profile and clinical trajectory compared to other neuromuscular EOS patients, supporting consideration of MMC as a separate subgroup within EOS classification systems to improve risk stratification and guide individualized treatment. Even within the current framework, recognizing MMC through a diagnosis-specific modifier may offer a practical means of improving risk stratification without requiring structural reclassification.</p>","PeriodicalId":21796,"journal":{"name":"Spine deformity","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spine deformity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s43390-026-01558-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The aim was to compare clinical and radiographic outcomes between myelomeningocele (MMC) and other neuromuscular early-onset scoliosis (EOS) patients following graduation from growing rod treatment and to evaluate whether MMC should be considered a distinct subgroup within the classification of EOS.
Methods: This single-center retrospective cohort study included 26 patients with neuromuscular EOS (10 with MMC, 16 with other neuromuscular etiologies) treated with traditional or magnetically controlled growing rods between 2004 and 2023, all of whom achieved graduation and had a minimum of 2-year of post-graduation follow-up. Demographic, clinical, radiographic, and complication data were analyzed. Complication burden was assessed using unplanned return to the operating room (UPROR), modified Clavien-Dindo-Sink grading, and negative binomial regression.
Results: Wound-related complications were significantly more frequent in the MMC group (80.0% vs. 6.2%, p = 0.002). The MMC patients had a higher complication burden (mean 3.3 ± 2.3 vs. 0.9 ± 1.4, p = 0.003), more multiple reoperations (≥ 2 UPROR: 70.0% vs. 0.0%, p = 0.007), more severe complications (modified Clavien-Dindo-Sink grade 3b: 70.0% vs. 25.0%, p = 0.016), and a 3.52-fold higher overall complication rate (IRR = 3.52, 95% CI 1.63-10.80). Spinal growth and sagittal alignment were also significantly compromised in the MMC patients.
Conclusion: MMC patients demonstrate a markedly distinct complication profile and clinical trajectory compared to other neuromuscular EOS patients, supporting consideration of MMC as a separate subgroup within EOS classification systems to improve risk stratification and guide individualized treatment. Even within the current framework, recognizing MMC through a diagnosis-specific modifier may offer a practical means of improving risk stratification without requiring structural reclassification.
期刊介绍:
Spine Deformity the official journal of the?Scoliosis Research Society is a peer-refereed publication to disseminate knowledge on basic science and clinical research into the?etiology?biomechanics?treatment?methods and outcomes of all types of?spinal deformities. The international members of the Editorial Board provide a worldwide perspective for the journal's area of interest.The?journal?will enhance the mission of the Society which is to foster the optimal care of all patients with?spine?deformities worldwide. Articles published in?Spine Deformity?are Medline indexed in PubMed.? The journal publishes original articles in the form of clinical and basic research. Spine Deformity will only publish studies that have institutional review board (IRB) or similar ethics committee approval for human and animal studies and have strictly observed these guidelines. The minimum follow-up period for follow-up clinical studies is 24 months.